{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:35:33Z","timestamp":1778819733873,"version":"3.51.4"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recombinant Factor VIII-Fc fusion protein (rFVIIIFc) is an enhanced half-life therapeutic protein product used for the management of hemophilia A. Recent studies have demonstrated that rFVIIIFc interacts with Fc gamma receptors (Fc\u03b3R) resulting in the activation or inhibition of various Fc\u03b3R-expressing immune cells. We previously demonstrated that rFVIIIFc, unlike recombinant Factor IX-Fc (rFIXFc), activates natural killer (NK) cells via Fc-mediated interactions with Fc\u03b3RIIIA (CD16). Additionally, we showed that rFVIIIFc activated CD16<jats:sup>+<\/jats:sup> NK cells to lyse a FVIII-specific B cell clone. Here, we used human NK cell lines and primary NK cells enriched from peripheral blood leukocytes to study the role of the FVIII moiety in rFVIIIFc-mediated NK cell activation. Following overnight incubation of NK cells with rFVIIIFc, cellular activation was assessed by measuring secretion of the inflammatory cytokine IFN\u03b3 by ELISA or by cellular degranulation. We show that anti-FVIII, anti-Fc, and anti-CD16 all inhibited indicating that these molecules were involved in rFVIIIFc-mediated NK cell activation. To define which domains of FVIII were involved, we used antibodies that are FVIII domain-specific and demonstrated that blocking FVIII C1 or C2 domain-mediated membrane binding potently inhibited rFVIIIFc-mediated CD16<jats:sup>+<\/jats:sup> NK cell activation, while targeting the FVIII heavy chain domains did not. We also show that rFVIIIFc binds CD16 with about five-fold higher affinity than rFIXFc. Based on our results we propose that FVIII light chain-mediated membrane binding results in tethering of the fusion protein to the cell surface, and this, together with increased binding affinity for CD16, allows for Fc-CD16 interactions to proceed, resulting in NK cellular activation. Our working model may explain our previous results where we observed that rFVIIIFc activated NK cells via CD16, whereas rFIXFc did not despite having identical IgG1 Fc domains.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1341013","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:46:22Z","timestamp":1712637982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation"],"prefix":"10.3389","volume":"15","author":[{"given":"H.A. Daniel","family":"Lagass\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuben E.","family":"Sauna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil","family":"Golding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.transci.2019.08.010","article-title":"The evolution of recombinant factor replacement for hemophilia","volume":"58","author":"Sankar","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1756188","article-title":"The more recent history of hemophilia treatment","volume":"48","author":"Franchini","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8584","DOI":"10.3390\/ijms24108584","article-title":"Plasma clearance of coagulation factor VIII and extension of its half-life for the therapy of hemophilia A: A critical review of the current state of research and practice","volume":"24","author":"Sarafanov","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.5.17334","article-title":"Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies","volume":"3","author":"Beck","year":"2011","journal-title":"mAbs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","article-title":"Fc fusion as a platform technology: potential for modulating immunogenicity","volume":"33","author":"Levin","year":"2015","journal-title":"Trends Biotechnol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"Rath","year":"2015","journal-title":"Crit Rev Biotechnol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024497","article-title":"Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization","volume":"2","author":"Kis-Toth","year":"2018","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00138","article-title":"Recombinant factor VIII fc inhibits B cell activation via engagement of the fc\u03b3RIIB receptor","volume":"11","author":"Georgescu","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1097\/HS9.0000000000000330","article-title":"Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via Fc\u03b3RIIa","volume":"4","author":"Kannicht","year":"2020","journal-title":"Hemasphere"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692157","article-title":"Factor VIII-fc activates natural killer cells via fc-mediated interactions with CD16","volume":"12","author":"Lagasse","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2022.1020852","article-title":"Recombinant factor VIII Fc fusion protein engages monocytes via Fc and FVIII domains to reduce monocyte differentiation into osteoclasts","volume":"1","author":"Duan","year":"2022","journal-title":"Front Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25874","article-title":"Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-fc fusion protein","volume":"63","author":"Groomes","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13413","article-title":"Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis","volume":"24","author":"Carcao","year":"2018","journal-title":"Haemophilia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/hae.14192","article-title":"Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe hemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis","volume":"27","author":"Carcao","year":"2021","journal-title":"Haemophilia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017780","article-title":"Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study","volume":"141","author":"Malec","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J Immunol Methods"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15817","article-title":"Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts","volume":"20","author":"Chun","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1951","article-title":"Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites","volume":"101","author":"Shi","year":"2003","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01841.x","article-title":"Role of lactadherin in the clearance of phosphatidylserine-expressing red blood cells","volume":"48","author":"Dasgupta","year":"2008","journal-title":"Transfusion"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.21.8417","article-title":"cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences","volume":"87","author":"Stubbs","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12076","article-title":"Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein","volume":"11","author":"Peters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"B27","unstructured":"DumontJS\n            BitontiAJ\n            PierceG\n            LukA\n            JiangH\n            MckinneyB\n          United States Patent and Trademark Office document\/patent number US-9050318-B22015"},{"key":"B28","unstructured":"PierceGT,S\n            PetersRT\n            JiangH\n          United States Patent and Trademark Office document\/patent number US-9670475-B22017"},{"key":"B29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12248-019-0336-8","article-title":"Fc-fusion drugs have fcgammaR\/C1q binding and signaling properties that may affect their immunogenicity","volume":"21","author":"Lagasse","year":"2019","journal-title":"AAPS J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11957","DOI":"10.1038\/s41598-019-48323-w","article-title":"The Fab portion of immunoglobulin G contributes to its binding to Fc\u03b3 receptor III","volume":"9","author":"Yogo","year":"2019","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2038531","DOI":"10.1080\/19420862.2022.2038531","article-title":"The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc\u00a0gamma receptor IIIa","volume":"14","author":"Yamaguchi","year":"2022","journal-title":"MAbs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.1c00832","article-title":"Biophysical characterization of the contribution of the fab region to the igG-fc\u03b3RIIIa interaction","volume":"62","author":"Kosuge","year":"2023","journal-title":"Biochemistry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/19420862.2018.1522178","article-title":"Antigen binding allosterically promotes Fc receptor recognition","volume":"11","author":"Zhao","year":"2019","journal-title":"MAbs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.str.2020.03.001","article-title":"Antigen-induced allosteric changes in a human igG1 fc increase low-affinity fc\u03b3 Receptor binding","volume":"28","author":"Orlandi","year":"2020","journal-title":"Structure"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.003","article-title":"Discoidin domains as emerging therapeutic targets","volume":"37","author":"Villoutreix","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(81)90278-3","article-title":"Sequence and expression of the discoidin I gene family in Dictyostelium discoideum","volume":"153","author":"Poole","year":"1981","journal-title":"J Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.3.539.539","article-title":"Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders","volume":"71","author":"Kane","year":"1988","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/46594","article-title":"Crystal structures of the membrane-binding C2 domain of human coagulation factor V","volume":"402","author":"Macedo-Ribeiro","year":"1999","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/46601","article-title":"Structure of the C2 domain of human factor VIII at 1.5 A resolution","volume":"402","author":"Pratt","year":"1999","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705195200","article-title":"Crystal structure of lactadherin C2 domain at 1.7A resolution with mutational and computational analyses of its membrane-binding motif","volume":"283","author":"Shao","year":"2008","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.5b00417","article-title":"Membrane interaction of the factor VIIIa discoidin domains in atomistic detail","volume":"54","author":"Madsen","year":"2015","journal-title":"Biochemistry"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1722187","article-title":"Uncovering membrane-bound models of coagulation factors by combined experimental and computational approaches","volume":"121","author":"Ohkubo","year":"2021","journal-title":"Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1040106","article-title":"Stable binding to phosphatidylserine-containing membranes requires conserved arginine residues in tandem C domains of blood coagulation factor VIII","volume":"9","author":"Peters","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12787","article-title":"Transplacental delivery of recombinant Fc-fused factor VIII (rFVIIIFc) in FVIII-deficient mice [abstract OC 37.1]","volume":"6","author":"Reyes Ruiz","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-367813","article-title":"Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs","volume":"119","author":"Dumont","year":"2012","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13700","article-title":"The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein","volume":"15","author":"Leksa","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxg076","article-title":"Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo","volume":"15","author":"Zocher","year":"2003","journal-title":"Int Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.32607\/20758251-2015-7-2-74-79","article-title":"Specific depletion of myelin-reactive B cells via BCR-targeting","volume":"7","author":"Stepanov","year":"2015","journal-title":"Acta\u00a0Naturae"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell Malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert Opin Biol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1341013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:46:25Z","timestamp":1712637985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1341013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2024.1341013"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1341013","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"article-number":"1341013"}}